ArticleProstate international2021

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study.

Takashi Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.